Key clinical point: Combination nivolumab and ipilimumab for advanced NSCLC was safe and showed encouraging clinical activity overall and in special populations.
Major finding: One-year DOR was 24%, 19% and 37%, and 1-year PFS was 26%, 25%, and 27% for patients with ECOG PS 2, ECOG PS0-1+comorbidities, and overall, respectively.
Study details: The single-arm, nonrandomized CheckMate 817 study of 589 patients.
Disclosures: CheckMate 817 was sponsored by Bristol-Myers Squibb. Dr. Barlesi disclosed financial relationships with Abbvie, ACEA, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, and Takeda.
Barlesi F et al. WCLC 2019: Abstract OA04.02.